Bioventus Inc
NASDAQ:BVS
Intrinsic Value
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of muscul... [ Read More ]
The intrinsic value of one BVS stock under the Base Case scenario is 11.11 USD. Compared to the current market price of 4.55 USD, Bioventus Inc is Undervalued by 59%.
Valuation Backtest
Bioventus Inc
Run backtest to discover the historical profit from buying and selling BVS stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Bioventus Inc
Current Assets | 249.5m |
Cash & Short-Term Investments | 26.8m |
Receivables | 112.9m |
Other Current Assets | 109.8m |
Non-Current Assets | 561.6m |
Long-Term Investments | 6.9m |
PP&E | 54m |
Intangibles | 500.8m |
Other Non-Current Assets | -100k |
Current Liabilities | 160.8m |
Accounts Payable | 17.6m |
Accrued Liabilities | 118.2m |
Other Current Liabilities | 25m |
Non-Current Liabilities | 472.8m |
Long-Term Debt | 375m |
Other Non-Current Liabilities | 97.8m |
Earnings Waterfall
Bioventus Inc
Revenue
|
502.8m
USD
|
Cost of Revenue
|
-186.7m
USD
|
Gross Profit
|
316.1m
USD
|
Operating Expenses
|
-337.9m
USD
|
Operating Income
|
-21.8m
USD
|
Other Expenses
|
-160.3m
USD
|
Net Income
|
-182.1m
USD
|
Free Cash Flow Analysis
Bioventus Inc
What is Free Cash Flow?
BVS Profitability Score
Profitability Due Diligence
Bioventus Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
Bioventus Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
BVS Solvency Score
Solvency Due Diligence
Bioventus Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Score
Bioventus Inc's solvency score is 35/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BVS Price Targets Summary
Bioventus Inc
According to Wall Street analysts, the average 1-year price target for BVS is 8.16 USD with a low forecast of 7.07 USD and a high forecast of 9.45 USD.
Ownership
BVS Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
BVS Price
Bioventus Inc
Average Annual Return | -52.77% |
Standard Deviation of Annual Returns | 41.78% |
Max Drawdown | -95% |
Market Capitalization | 287.1m USD |
Shares Outstanding | 63 101 172 |
Percentage of Shares Shorted | 2% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.
Contact
IPO
Employees
Officers
The intrinsic value of one BVS stock under the Base Case scenario is 11.11 USD.
Compared to the current market price of 4.55 USD, Bioventus Inc is Undervalued by 59%.